COMPANY

Senseonics

HQ: Germantown, MD source · senseonics.com ↗

Location: Germantown, MD · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Diabetes Mellitus Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus Diabetes Type 1 Diabetes Melletus Continuous Glucose Monitoring System Eversense® CGM System Eversense (Senseonics) Continuous Glucose Monitoring System

$165.5MRaised (2 yrs)11Trials (company is sponsor)

Timeline

May 4, 2026 Raise Follow-on offering: $92M (total, as published), announced May 4, 2026. Source: company release on GlobeNewswire. source ↗
May 4, 2026 Debt Debt: $140M (not counted as a raise), announced May 4, 2026. Source: company release on GlobeNewswire. source ↗
Feb 12, 2026 Trial start Not phased (device or behavioral study): ROME GS System Study source ↗
Dec 29, 2025 Trial start Not phased (device or behavioral study): Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature source ↗
May 21, 2025 Raise Follow-on offering: $57.5M (total, as published), announced May 21, 2025. Source: company release on GlobeNewswire. source ↗
Oct 25, 2024 Raise Follow-on offering — Registered direct: $16M (total, as published), announced Oct 25, 2024. Source: company release on GlobeNewswire. source ↗
Oct 20, 2021 Trial start Not phased (device or behavioral study): Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features source ↗
Apr 13, 2021 Trial start Not phased (device or behavioral study): Eversense® Non-adjunctive Use Post Approval Study source ↗
Mar 19, 2019 Trial start Not phased (device or behavioral study): Post Approval Study of the Eversense® Continuous Glucose Monitoring source ↗
Dec 27, 2018 Trial start Not phased (device or behavioral study): PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days source ↗
Jul 25, 2017 Trial start Not phased (device or behavioral study): PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm source ↗
2016-10 Trial start Not phased (device or behavioral study): A Feasibility Trial to Evaluate the Senseonics Continuous Glucose Monitoring System in Canada source ↗
2016-10 Trial start Not phased (device or behavioral study): Home Use Sensor Study source ↗
2016-01 Trial start Not phased (device or behavioral study): Evaluation of the Accuracy of an Implanted Glucose Sensor source ↗
2014-05 Trial start Not phased (device or behavioral study): PRECISE: A Prospective, Multi-Center Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor source ↗

Upcoming milestones

2027-12 (ESTIMATED) · Not phased · Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature · NCT07386340
2028-08 (ESTIMATED) · Not phased · ROME GS System Study · NCT07518004

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $165.5M · Debt: $140.0M. Last 2 years.

May 4, 2026 Follow-on offering: $92M (total, as published), announced May 4, 2026. Source: company release on GlobeNewswire. source ↗
May 21, 2025 Follow-on offering: $57.5M (total, as published), announced May 21, 2025. Source: company release on GlobeNewswire. source ↗
Oct 25, 2024 Follow-on offering — Registered direct: $16M (total, as published), announced Oct 25, 2024. Source: company release on GlobeNewswire. source ↗
May 4, 2026 Debt: $140M (not counted as a raise), announced May 4, 2026. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 11

Record	Title	Phase	Status	Start	Primary completion
NCT07386340	Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature	Not phased (device or behavioral study)	Recruiting	Dec 29, 2025	2027-12 (estimated)
NCT07518004	ROME GS System Study	Not phased (device or behavioral study)	Recruiting	Feb 12, 2026	2028-08 (estimated)
NCT04836546	Eversense® Non-adjunctive Use Post Approval Study	Not phased (device or behavioral study)	Active, not recruiting	Apr 13, 2021	Mar 31, 2026 (estimated)
NCT03908125	Post Approval Study of the Eversense® Continuous Glucose Monitoring	Not phased (device or behavioral study)	Completed	Mar 19, 2019	Feb 1, 2024 (actual)
NCT03808376	PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days	Not phased (device or behavioral study)	Completed	Dec 27, 2018	May 8, 2020 (actual)
NCT03251079	PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm	Not phased (device or behavioral study)	Completed	Jul 25, 2017	Feb 1, 2018 (actual)
NCT05131139	Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features	Not phased (device or behavioral study)	Unknown status (ClinicalTrials.gov)	Oct 20, 2021	Mar 30, 2025 (estimated)
NCT02647905	Evaluation of the Accuracy of an Implanted Glucose Sensor	Not phased (device or behavioral study)	Completed	2016-01	2016-07 (actual)
NCT02933164	A Feasibility Trial to Evaluate the Senseonics Continuous Glucose Monitoring System in Canada	Not phased (device or behavioral study)	Unknown status (ClinicalTrials.gov)	2016-10	2017-08 (estimated)
NCT02932514	Home Use Sensor Study	Not phased (device or behavioral study)	Unknown status (ClinicalTrials.gov)	2016-10	2017-07 (estimated)
NCT02154126	PRECISE: A Prospective, Multi-Center Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor	Not phased (device or behavioral study)	Completed	2014-05	2015-11 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2024-11-08 Raise Private raise (SEC Form D): $16.0M sold; issuer “Senseonics Holdings, Inc.”. Verified from the SEC filing. SEC filing ↗